Health
Article reserved for subscribers
The Danish and American leaders in the sector are prospering on the stock market. Although not marketed in France, their treatments will soon be produced there thanks to considerable investments.
Soon Ozempic, Wegovy and even Zepbound will be “made in France”… even though these anti-obesity treatments are not yet marketed in France. At the end of November 2023, the Danish giant Novo Nordisk invested more than 2 billion euros in its Chartres factory, which produces these anti-diabetic and anti-obesity treatments. Visiting the site, Emmanuel Macron welcomed an investment “unprecedented for the pharmaceutical industry in France”. More than 500 new jobs will be created, in addition to the 1,600 employees already present, with a doubling of production capacity thanks to an increase in the surface area of the site to 230,000 m² by 2028.
Since 2010, Novo Nordisk had already invested more than 450 million euros in France, including 130 million at the start of 2023 for new assembly and packaging lines. Its Chartres site mainly produces injector pens intended for diabetic patients. M
